Equity (Details Narrative) - USD ($)						1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 05, 2024	Dec. 04, 2024	Dec. 01, 2023	Oct. 11, 2023	Feb. 15, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 03, 2024	Dec. 31, 2023	Oct. 04, 2023	Feb. 14, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized							300,000,000		300,000,000			300,000,000
Common stock, par value							$ 0.0001		$ 0.0001			$ 0.0001
Minimum bid price							$ 18.00		$ 18.00				$ 9.00
Shares issued value									$ 1,795,000
Cash												$ 4,000
Liability							99,217,000		99,217,000			$ 96,264,000
Change in fair value of contribution liability							(180,000)		240,000
Net income loss							(5,528,000)	(14,087,000)	$ (9,763,000)	(97,610,000)
Option to purchase shares
Fair value of a non-statutory stock option per share
Expected volatility					75.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term					6 years 6 months
Risk free interest rate					4.00%
Unvested stock option awards granted							$ 1,100,000		$ 1,100,000
Weighted average remaining contractual life, granted									1 year 4 months 24 days
Stock option exercised									$ 0
Common stock, shares issued							34,868,628		34,868,628			34,649,046
Founder Shares [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Voting interests percentage							100.00%		100.00%
Founder Shares [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares issued							17,454,542		17,454,542
Founder Shares [Member] | Poseidon Bio LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Ownership percentage							68.00%		68.00%
Non-employee Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value of a non-statutory stock option per share					$ 3.73
Share based compensation						$ 600,000	$ 200,000		$ 600,000
2022 Stock Option and Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based compensation arrangement by share-based payment award, shares issued in period									4,360,000
Board of Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Option to purchase shares					75,000				75,000
Class of warrant or right, exercise price of warrants or rights					$ 10.00
2022 Employee Stock Purchase Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant							2,180,000		2,180,000
Employee stock purchase plan percentage									85.00%
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued value
Issuance of common stock, Shares									169,582
Net income loss
Class of warrant or right, exercise price of warrants or rights														$ 8.06
Virion Therapeutics LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net income loss							$ 1,000,000.0		$ 6,600,000
Contribution Agreement [Member] | Virion Therapeutics LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other accrued interest rate				50.00%
Cash				$ 4,100,000
Issuance of common stock, Shares			500,000	250,000
Liability				$ 2,800,000
Increase in liability							3,400,000		200,000
Change in fair value of contribution liability							200,000		200,000
Net income loss							$ 500,000		$ 3,300,000
Contribution Agreement [Member] | Virion Therapeutics LLC [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period purchases of shares				750,000
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Minimum bid price											$ 1
Shares issued value	$ 35,000,000	$ 35,000,000